We evaluated the clinical relevance of tumor‐infiltrating lymphocytes (TILs) and four cell cycle regulation biomarkers-Ki67, MCM2, Cyclin A, and PHH3-across major breast cancer subtypes in a contemporary real‐world cohort.<h4>Methods</h4>We conducted a retrospective analysis of the outcomes of 398 patients with advanced breast cancer treated between 2020 and 2024. This evidence concerns the gene MKI67 and breast carcinoma.